Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Vorinostat is a potent and well tolerated HDAC inhibitor. It has been reported to enhance
radiosensitivity of cancer cells. We hypothesize that the addition of vorinostat to WBRT may
increase therapeutic efficacy for patients with brain metastases.